Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8NEV4

UPID:
MYO3A_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8NEV4; Q4G0X2; Q5VZ28; Q8WX17; Q9NYS8

BACKGROUND:
The protein Myosin-IIIa, with the recommended name and unique identifier Q8NEV4, plays an essential role in vision and hearing. It is required for the proper development of cochlear hair bundles, influencing their morphology and the elongation of actin in stereocilia tips. This protein transports the actin regulatory factor ESPN to the plus ends of actin filaments, thereby playing a pivotal role in the architecture of the auditory hair bundle.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the development and function of cochlear hair bundles, Myosin-IIIa is directly linked to Deafness, autosomal recessive, 30. This connection highlights the protein's potential as a target for therapeutic intervention in hearing loss disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.